Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events.
Hiroshi Kadowaki1, Hiroshi Akazawa1, Junichi Ishida1
1Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
JMA Journal
|May 17, 2021
Summary
Immune checkpoint inhibitors (ICIs) can cause rare but fatal cardiac adverse events (CAEs). Onco-cardiology research is urgently needed to understand and manage these life-threatening conditions in cancer patients.
Area of Science:
- Cardiology
- Oncology
- Immunology
Background:
- Onco-cardiology addresses cancer therapeutics-related cardiac adverse events (CAEs).
- Immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment but can cause immune-related adverse events (irAEs).
- Cardiac irAEs from ICIs, including myocarditis and arrhythmias, are rare but potentially fatal.
Purpose of the Study:
- To highlight the emergence and importance of onco-cardiology.
- To discuss the cardiac implications of immune checkpoint inhibitors (ICIs).
- To emphasize the urgent need for research into the pathophysiology and management of ICI-related cardiac adverse events (CAEs).
Main Methods:
- Literature review on ICI-related cardiac adverse events.
- Analysis of reported cases of cardiac irAEs.
- Discussion of current understanding of ICI cardiotoxicity.
Main Results:
- ICI therapy can lead to serious cardiac adverse events (CAEs).
- Manifestations include myocarditis, arrhythmias, conduction abnormalities, pericardial disease, and potentially Takotsubo-like cardiomyopathy.
- While rare, these events pose a significant threat to patient survival.
Conclusions:
- ICI-related CAEs represent a critical challenge in onco-cardiology.
- Further research into the pathophysiology of these events is essential.
- Developing effective management strategies is crucial for patient care and treatment continuity.
More Related Videos
Related Concept Videos
01:14Myocarditis III: Medical Management
45
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
45
01:22Myocarditis IV: Nursing Management
78
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
78
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
645
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
645
01:17Pericarditis III: Medical Management
81
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
81
01:26Heart Failure Drugs: Inotropic Agents
905
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
905
01:30Heart Failure V: Medical Management
64
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
64